Instruction for use: Quifenadine

The Latin name of the substance Quifenadine

Chifenadinum (genus. Chifenadini)

Chemical name

Alpha, alpha-Diphenyl-3-quinuclidine methanol (and as hydrochloride)

Gross formula

C₂₀H₂₃NO

Pharmacological group

H1-Antihistamines

The nosological classification (ICD-10)

J30 Vasomotor and allergic rhinitis: Allergic rhinopathy; Allergic rhinosinusopathy; Allergic diseases of the upper respiratory tract; Allergic rhinitis; Allergic rhinitis seasonal; Vasomotor runny nose; Prolonged allergic rhinitis; All-year-round allergic rhinitis; All-year allergic rhinitis; Year-round or seasonal allergic rhinitis; All-the-year-round rhinitis of an allergic nature; Rhinitis vasomotor allergic; Exacerbation of pollinosis in the form of rhinoconjunctival syndrome; Acute allergic rhinitis; Edema of the nasal mucosa; Edema of the nasal mucosa; Edema of the mucous membrane of the nasal cavity; Swelling of the nasal mucosa; Swelling of the nasal mucosa; Pollinosis; Permanent allergic rhinitis; Rhinoconjunctivitis; Rhinosinusitis; Rhinosinusopathy; Seasonal allergic rhinitis; Seasonal allergic rhinitis; Hay rhinitis; Chronic allergic rhinitis; Allergic diseases of the respiratory tract

J44 Other chronic obstructive pulmonary disease: Allergic bronchitis; Bronchitis allergic; Asthmatic bronchitis; Bronchitis obstructive; Disease of the bronchi; Difficult sputum separation in acute and chronic respiratory diseases; Cough with inflammatory diseases of the lungs and bronchi; Reversible bronchial obstruction; Reversible obstructive airway disease; Obstructive bronchial disease; Obstructive pulmonary disease; Obstructive bronchitis; Spastic bronchitis; Chronic lung diseases; Chronic nonspecific lung diseases; Chronic Obstructive Pulmonary Diseases; Chronic obstructive bronchitis; Chronic obstructive airways disease; Chronic obstructive pulmonary disease; Restrictive pathology of the lungs

L20 Atopic dermatitis: Allergic diseases of the skin; Allergic skin disease noninfectious etiology; Allergic skin disease etiology nemikrobnoy; Allergic skin diseases; Allergic skin lesions; Allergic reactions on the skin; atopic dermatitis; Allergic dermatosis; Allergic diathesis; Allergic itching dermatosis; Allergic skin disease; Allergic skin irritation; allergic Dermatitis; atopic Dermatitis; allergic dermatoses; exudative diathesis; Itchy atopic eczema Itchy allergic dermatosis; Allergic skin disease; Cutaneous allergic reaction to drugs and chemicals; Cutaneous reactions to medications; Skin and allergic disease; Acute eczema; common neurodermatitis; Chronic atopic dermatitis; Exudative diathesis

L29 Itching: Itching with partial obstruction of the biliary tract; Dermatitis itchy; Dermatosis with persistent itching; Other itching dermatoses; Itching dermatoses; Itching allergic dermatosis; Itching dermatitis; Itching dermatosis; Itching itch; Excruciating itching; Severe itching; Endogenous itching; Skin itching with dermatosis; Restricted itchy dermatitis; Itching of the skin; Itchy scalp; Itching eczema

L30.9 Unspecified Dermatitis: Allergic dermatoses complicated by a secondary bacterial infection; Anal eczema; Bacterial maturation; Varicose Eczema; Venous dermatitis; Inflammation of the skin; Inflammation of the skin upon contact with plants; Inflammatory Skin Disease; Inflammatory Skin Diseases; Inflammatory Skin Diseases; Inflammatory skin reactions; Inflammatory processes of the skin; Hypostatic dermatitis; Fungal Eczema; Fungal dermatosis; Dermatitis; Dermatitis is stagnant; Dermatitis and eczema in the anal area; Dermatitis acute contact; Perianal dermatitis; Dermatosis; Dermatosis of the scalp; Dermatosis of psoriasis; Dermatosis with persistent itching; Dermatoses; Dermatoses itchy; Other itching dermatoses; Significant eczematous manifestations; Itching with dermatoses; Itching eczema; Itching dermatoses; Itching dermatitis; Itching dermatosis; True eczema; Skin reaction to insect bites; Skin itching with dermatosis; Constitutional eczema; Weeping eczema; Drowsing inflammatory skin disease; Dying Infectious-Inflammatory Skin Disease; Non-allergic dermatitis; Nummular eczema; Acute contact eczema; Acute inflammatory skin disease; Acute dermatosis; Acute severe dermatosis; Perianal dermatitis; Superficial dermatosis; Subacute Contact Eczema; Simple dermatitis; Occupational dermatitis; Psychogenic dermatosis; Bubble dermatitis of newborns; Pustular eruptions; Irritation and redness of the skin; Low-flammable eczema; Dry atrophic eczema; Dry eczema; Toxic dermatitis; Ear eczema like dermatitis; Chronic eczema; Chronic dermatosis; Chronic dermatosis; Chronic common dermatosis; Scaly papular dermatosis; Eczema; Eczema anal region; Eczema of the hands; Eczema Contact; Eczema lichenized; Eczema Nummular; Eczema acute; Eczema acute contact; Eczema subacute; Eczematous dermatitis; Eczema-like rashes; Ecome exogenous; Endogenous eczema; Gluteal dermatitis; Limited itching dermatitis

L40 Psoriasis: Chronic plaque psoriasis with diffuse; generalized psoriasis; Psoriasis of the scalp; hairy parts of the skin; A generalized form of psoriasis; Psoriazoformny dermatitis; Psoriasis complicated with erythroderma; disabling psoriasis; Isolated psoriatic plaque; Eksfolliativny psoriasis; psoriatic erythroderma; Psoriasis with eczematization; Hyperkeratosis in psoriasis; Inverse psoriasis; Psoriasis ekzemopodobnye; dermatoses psoriazoformny; Psoriasis genitals; Psoriasis lesions with hairy areas of the skin; erythrodermic psoriasis; Chronic psoriasis of the scalp; Chronic psoriasis; ordinary psoriasis; refractory psoriasis; Koebner phenomenon; psoriasis

L50.0 Allergic urticaria: Skin reaction to medication

T78.1 Other manifestations of a pathological reaction to food: Allergic reactions to food; Allergy to cow's milk proteins; Allergy to proteins of mother's milk; Allergy food; Artificial feeding of children from birth with intolerance to cow's milk proteins; Multiple food allergies; Disturbance of assimilation of milk food; Disturbance of food assimilation; Intolerance to cow's milk protein in infants; Intolerance to cow's milk proteins; Intolerance to cow's milk; Intolerance to certain foods; Food allergy; Food and drug allergy; Food intolerance; Bowel irritation from food

T78.3 Angioedema: Edema Quincke; Laryngeal exacerbation with angioneurotic edema; Recurrent angioedema; Allergic edema; Recurrent swelling of Quincy

Y57 Adverse reactions in the therapeutic use of other and unspecified drugs and medications

CAS Code

10447-39-9

Characteristics of the substance Quifenadine

The quinuclidine derivative. White crystalline powder odorless, bitter taste. It is insoluble in water and alcohol.

Pharmacology

Pharmacological action - anti-allergic, antihistamine.

It blocks histamine H1 receptors. Activates diaminoksidazu - enzyme, inactivating histamine, and reduces the content of the mediator in the tissues. Weaken the spasmogenic effect of histamine on the smooth muscles of the bronchi and intestines, reduce its hypotensive effect and influence on the permeability of blood vessels. Has moderate antiserotoninovoe, mestnoanesteziruyuschee and insignificant holinoliticheskoe action.

After oral administration, approximately 45% of hifenadine is rapidly absorbed from the gastrointestinal tract and is found in the tissues of the body after 30 minutes. Cmax in blood plasma is achieved after 1 hour. The highest content of hifenadine is noted in the liver, slightly less in the lungs and kidneys, the lowest in the brain (hifenadine has low lipophilicity, poorly penetrates the BBB, and has no pronounced inhibitory effect on the central nervous system). Metabolised in the liver. Metabolites are excreted in the urine, bile and through the lungs. A non-adsorbed part of the drug is excreted through the intestine.

The duration of action is 6-8 hours.

Application of substance Quifenadine

Pollinosis, allergic rhinitis, urticaria, eczema, psoriasis, neurodermatitis, itching, allergic complications associated with the use of drugs or food intake, non-infectious allergic reactions with the bronchospastic component, angioedema.

Contraindications

Hypersensitivity, pregnancy, breast-feeding.

Restrictions on the use

Severe diseases of the cardiovascular system, liver and kidney, peptic ulcer of the stomach and duodenum.

Application in pregnancy and lactation

In pregnancy (especially in the first trimester) it is possible if the expected effect of therapy exceeds the potential risk to the fetus. For the duration of treatment, breastfeeding should be stopped.

Side effects of Quifenadine

Dryness of the oral mucosa, dyspeptic phenomena, sedation.

Interaction

Increases the absorption of slowly absorbed drugs (for example, anticoagulants of indirect action - coumarins). Does not enhance the depressing effect on the central nervous system alcohol and hypnotics.

Overdose

Symptoms: dryness of the mucous membranes, headache, vomiting, abdominal pain and other dyspeptic phenomena.

Treatment: gastric lavage, reception of activated charcoal, symptomatic therapy.

Routes of administration

Inside.

Precautions for the substance Quifenadine

Due to individual hypersensitivity, a weak sedative effect is possible, therefore, when appointing people whose work requires a quick mental or motor reaction (drivers of vehicles, etc.) should be preliminarily determined (by short-term appointment), whether the patient is observed after taking hifenadine sedative effect.